Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.
Mazyar Shadman, MD, MPH, an oncologist at Seattle Cancer Care Alliance and associate professor of Oncology at the University of Washington, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).
MB-106 is an novel CD20 chimeric antigen receptor (CAR) T-cell therapy. A study evaluating its efficacy and safety of MB-106 was recently presented during the Transplantation & Cellular Therapy Meetings.
According to Shadman, CD20 CAR T-cell therapy was explored similarly to the other FDA approved CAR T cells.
0:08 | Patients with relapsed refractory CD20 positive B-cell malignancies were eligible including CLL. Each histology had a specific inclusion and exclusion criteria for large cell lymphoma versus CLL versus follicular lymphoma we have had a specific eligibility criteria but basically they had to be in the relapsed refractory setting as part of the study the CD 20 expression needed to be confirmed. Otherwise, the method was very similar to two other FDA approved autologous CAR T products.
0:47 | Patients would after enrollment they would go undergo look of phrases and in the meantime, while the cells were being manufactured the some patients needed bridging therapy. When cells were ready, they received chemo using to fludarabine and cyclophosphamide. And after 2 days of rest, they receive their cell dose. We had disease assessment at day 28 including a PET scan and bone marrow biopsy, if necessary.